抗血小板联合抗凝药物治疗冠心病合并下肢动脉闭塞的临床效果

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (575 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of antiplatelet combined with anticoagulant drugs on patients with coronary heart disease complicated with lower limb artery occlusion.Methods A total of 104 patients with coronary heart disease combined with treatment in hospitalization in Fushun City Hospital of Traditional Chinese Medicine from January 2019 to December 2020.According to random number table method,they were divided into monoclonal antibody group (n=52) and double antibody group (n=52).Both groups received routine examination and basic treatment after admission.In addition to the basic treatment,the monoclonal antibody group was given Aspirin enteric-coated tablet,and the double antibody group was given Rivaroxaban tablet in addition to the monoclonal antibody group.The intervention lasted for 8 weeks in both groups.The Seattle Scale (SAQ) score,treatment effect of lower extremity arteriosclastic oblusion,quality of life score (SF-36),ankle-brachial index (ABI),activated partial thrombin time (APTT),prothrombin time (PT) and platelet (PLT) were compared between two groups before and after treatment.Results There was no significant difference in SAQ score between the two groups before and after treatment (P＞0.05).There was no significant difference in ABI between the two groups before treatment (P＞0.05).After treatment,the ABI of the two groups was higher than before,and the ABI of the double antibody group was higher than that of the monoclonal antibody group,the differences were statistically significant (P＜0.05).There was no significant difference in SF-36 score before treatment (P＞0.05).After treatment,the SF-36 score of the two groups were higher than those before treatment,and the SF-36 score of the double antibody group was higher than that of the monoclonal antibody group,the differences were statistically significant (P＜0.05).There were no significant differences in APTT,PT and PLT between two groups before and after treatment (P＞0.05).Conclusion Aspirin combined with Rivaroxaban treatment of coronary heart disease combined with lower extremity arteriosclerosis can be brought to thrombin to form a thrombosis,thereby improving the treatment of patients to improve the patient′s ABI level.

Key words： Antiplatelet drugs Anticoagulant drugs Coronary heart disease Lower extremity arteriosclerosis Clinical efficacy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	BAI Sen

Cite this article:

BAI Sen. Clinical effect of antiplatelet combined with anticoagulant in the treatment of coronary heart disease complicated with lower limb arterial occlusion[J]. 中国当代医药, 2022, 29(3): 17-20转24.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I3/17

[1]	胡盛寿，高润霖，刘力生，等.《中国心血管病报告2018》概要[J].中国循环杂志，2019，34（3）：209-220.
[2]	国家卫生计生委合理用药专家委员会，中国药师协会.冠心病合理用药指南（第2 版）[J].中国医学前沿杂志（电子版），2018，10（6）：1-130.
[3]	刘俊华，朱吉海，武建英.下肢动脉硬化闭塞症的治疗现状[J].中西医结合心血管病电子杂志，2018，6（29）：18-19，21.
[4]	中华医学会心血管病学分会介入心脏病学组，中华医学会心血管病学分会动脉粥样硬化与冠心病学组，中国医师协会心血管内科医师分会血栓防治专业委员会，等.稳定性冠心病诊断与治疗指南[J].中华心血管病杂志，2018，46（9）：680-694.
[5]	朱晴，牛轶.阿司匹林联合氯吡格雷、双嘧达莫在下肢动脉硬化闭塞症中治疗效果及对血小板功能的影响[J].中国老年学杂志，2021，41（10）：2117-2120.
[6]	张俊萍，孟庆斌，张新宇，等.双丹颗粒对冠状动脉粥样硬化性心脏病患者西雅图心绞痛量表评分和Adropin 蛋白水平的影响[J].中国医药，2018，13（10）：1453-1456.
[7]	中华医学会外科学分会血管外科学组.下肢动脉硬化闭塞症诊治指南[J].中华普通外科学文献（电子版），2016，10（1）：1-18.
[8]	张伟民，陈谨献，陈豪，等.琥珀酸美托洛尔联合胺碘酮对心律失常患者心功能及生活质量评分的影响[J].中国临床保健杂志，2020，23（2）：233-236.
[9]	赵智慧，潘云红.美托洛尔与曲美他嗪联合治疗老年冠心病心力衰竭对患者心功能和炎症因子的影响[J].中国现代医生，2021，59（5）：50-52，56.
[10]	邱鸿伟，陈校春，梁志豪.氯吡格雷与阿司匹林治疗冠心病的效果比较[J].中国当代医药，2021，28（1）：81-83.
[11]	杨震宇.复方丹参滴丸联合西药治疗糖尿病下肢动脉硬化闭塞症的临床效果观察[J].医学理论与实践，2021，34（11）：1872-1874.
[12]	乔威，唐亮，夏成勇，等.小檗碱联合西洛他唑治疗下肢动脉硬化闭塞症的疗效及机制[J].中国临床研究，2021，34（2）：145-149，154.
[13]	王继雪，赵钢，于文慧，等.双抗对照单抗血小板聚集治疗下肢动脉硬化闭塞症效果的Meta 分析[J].中国中西医结合外科杂志，2020，26（6）：1159-1164.
[14]	关雪冰.氯吡格雷联合阿司匹林治疗老年冠心病的临床观察[J].中国冶金工业医学杂志，2021，38（3）：323.
[15]	Rajpurkar M，Zia A，Weyand AC，et al.Management of anticoagulation associated reproductive tract bleeding in adolescent and young adult females-Results of a multinational survey[J].Thromb Res，2021，203：63-68.
[16]	叶晔，翟占强，刘庆宪.Xa 因子水平指导直接口服抗凝药物的急性脑梗死患者静脉溶栓治疗的疗效与安全性[J].心脑血管病防治，2021，21（2）：203-205.
[17]	王宁，郭振江，张媛媛，等.利伐沙班与低分子肝素治疗中心静脉置入设备相关性上肢深静脉血栓的疗效比较[J].天津医药，2021，49（4）：432-435.
[19]	侯微，冯鑫，张金红，等.利伐沙班在儿童血栓栓塞性疾病中的研究进展[J].中国药学杂志，2021，56（4）：270-275.
[20]	陈伟，钟莉，熊智巍.利伐沙班联合抗血栓压力泵对骨科术后深静脉血栓形成的预防作用[J].临床和实验医学杂志，2021，20（5）：511-515.
[18]	De Vriese AS，Caluwé R，Van Der Meersch H，et al.Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation：A Multicenter Randomized Controlled Trial[J].J Am Soc Nephrol，2021，32（6）：1474-1483.